Joseph J. Oleynek - Concepedia

Author

Joseph J. Oleynek

Pfizer (United States)

Also Known As

J J Oleynek, J. J. OLEYNEK, JOSEPH J. OLEYNEK, Joseph J Oleynek, Joseph J. Oleynek, Joseph Oleynek

Publications

537

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)W.E. Upjohn Institute for Employment Research Sterling Research Group (United States)Sterling Research Group

About

Joseph J. Oleynek is an author at Pfizer (United States) specializing in medicine, pharmacology, and physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	257
2	Biochemistry	4	4	103
3	Natural Sciences	1	1	51
4	Metabolism	1	1	18
5	Microbiology	1	1	18

Joseph J. Oleynek

Publications

530

Citations

H-Index

Page 1

	Year	Citations
Expression of the Rat Adrenomedullin Receptor or a Putative Human Adrenomedullin Receptor Does Not Correlate with Adrenomedullin Binding or Functional Response Scott P. Kennedy, Dexue Sun, Joseph J. Oleynek, Biochemical and Biophysical Research Communications Adrenal GlandFunctional ResponseMedicinePhysiologyNeuroendocrine Mechanism	1998	96
3‘-Aminoadenosine-5‘-uronamides: Discovery of the First Highly Selective Agonist at the Human Adenosine A <sub>3</sub> Receptor Michael P. DeNinno, Hiroko Masamune, Lois K. Chenard, Journal of Medicinal Chemistry	2002	59
Antimycins, Inhibitors of ATP-Citrate Lyase, from a Streptomyces sp. Colin J. Barrow, Joseph J. Oleynek, Vincent Marinelli, The Journal of Antibiotics	1997	58
Relative Importance of Adenosine A1and A3Receptors in Mediating Physiological or Pharmacological Protection from Ischemic Myocardial Injury in the Rabbit Heart Roger J. Hill, Joseph J. Oleynek, William P. Magee, Journal of Molecular and Cellular Cardiology Cardiac MuscleHeart FailureMolecular PhysiologyCardiogenic ShockCardiovascular Disease	1998	58
Novel<i>N</i><sup>6</sup>-substituted adenosine 5′-<i>N</i>-methyluronamides with high selectivity for human adenosine A<sub>3</sub>receptors reduce ischemic myocardial injury W. Ross Tracey, William P. Magee, Joseph J. Oleynek, American Journal of Physiology-Heart and Circulatory Physiology PharmacotherapyExperimental PharmacologyMolecular PharmacologyMedicinal ChemistryIschemic Myocardial Injury	2003	51
WIN 64821, a novel neurokinin antagonist produced by an Aspergillus sp. Joseph J. Oleynek, David M. Sedlock, Colin J. Barrow, The Journal of Antibiotics	1994	44
Cloning, Expression and Pharmacological Characterization of Rabbit Adenosine A1 and A3 Receptors Roger J. Hill, Joseph J. Oleynek, Christopher F. Hoth, Journal of Pharmacology and Experimental Therapeutics	1997	36
Characterization of K+ channel-dependent as well as -independent components of pinacidil-induced vasodilation. Kaushik D. Meisheri, M A Swirtz, Suresh Purohit, Journal of Pharmacology and Experimental Therapeutics	1990	34
The hydrophobic tunnel present in LOX-1 is essential for oxidized LDL recognition and binding Omar L. Francone, Meihua Tu, Lori Royer, Journal of Lipid Research	2008	25
A sensitive in vitro functional assay to detect K+ — channel-dependent vasodilators Kaushik D. Meisheri, Loretta A. Cipkus Dubray, Joseph J. Oleynek Journal of Pharmacological Methods Signal TransductionMolecular PhysiologyBiochemistryMedicineVascular Pharmacology	1990	20

Page 1